title: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer.
abstract: BACKGROUND
  Association of excision repair cross-complementing gene 1 (ERCC1) expression and treatment response and survival was evaluated in advanced stages of gastric cancer patients who were given different platinum-based chemotherapy.
  
  
  METHODS
  Forty-one patients with advanced gastric cancer were enrolled into the study from January 2000 to December 2009. ERCC1 expression was evaluated by immunohistochemistry (IHC).
  
  
  RESULTS
  Thirteen of the 41 patients (31%) were shown to have ERCC1 positive lesions. Although the clinical benefit from platin based chemotherapy was the same for ERCC1 positive and negative patients, survival times were statistically significantly better in ERCC1 negative gastric cancer patients.
  
  
  CONCLUSIONS
  We suggest that IHC studies for ERCC1 may be useful in prediction of the clinical outcome of advanced gastric cancer patients treated with platin-based chemotherapy.
authors.affiliation: Department of Medical Oncology, Medical Faculty, Erciyes University, Kayseri, Turkey. metino@erciyes.edu.tr
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Ismail Hakki
authors.initials: IH
authors.lastname: Akbudak
authors.forename: Kemal
authors.initials: K
authors.lastname: Deniz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Dikilitas
authors.forename: Gamze Gokoz
authors.initials: GG
authors.lastname: Dogu
authors.forename: Veli
authors.initials: V
authors.lastname: Berk
authors.forename: Halit
authors.initials: H
authors.lastname: Karaca
authors.forename: Ozlem
authors.initials: O
authors.lastname: Er
authors.forename: Mustafa
authors.initials: M
authors.lastname: Altinbas
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002945:Cisplatin / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin